Nature Communications (Apr 2024)
Author Correction: Molecular and phenotypic characteristics of RSV infections in infants during two nirsevimab randomized clinical trials
- Bahar Ahani,
- Kevin M. Tuffy,
- Anastasia A. Aksyuk,
- Deidre Wilkins,
- Michael E. Abram,
- Ron Dagan,
- Joseph B. Domachowske,
- Johnathan D. Guest,
- Hong Ji,
- Anna Kushnir,
- Amanda Leach,
- Shabir A. Madhi,
- Vaishali S. Mankad,
- Eric A. F. Simões,
- Benjamin Sparklin,
- Scott D. Speer,
- Ann Marie Stanley,
- David E. Tabor,
- Ulrika Wählby Hamrén,
- Elizabeth J. Kelly,
- Tonya Villafana
Affiliations
- Bahar Ahani
- Bioinformatics, Vaccines & Immune Therapies, BioPharmaceuticals R&D, AstraZeneca
- Kevin M. Tuffy
- Translational Medicine, Vaccines & Immune Therapies, BioPharmaceuticals R&D, AstraZeneca
- Anastasia A. Aksyuk
- Translational Medicine, Vaccines & Immune Therapies, BioPharmaceuticals R&D, AstraZeneca
- Deidre Wilkins
- Translational Medicine, Vaccines & Immune Therapies, BioPharmaceuticals R&D, AstraZeneca
- Michael E. Abram
- Translational Medicine, Vaccines & Immune Therapies, BioPharmaceuticals R&D, AstraZeneca
- Ron Dagan
- The Shraga Segal Department of Microbiology, Immunology and Genetics, Faculty of Health Sciences of the Ben-Gurion University of the Negev
- Joseph B. Domachowske
- State University of New York Upstate Medical University
- Johnathan D. Guest
- Virology and Vaccine Discovery, Vaccines & Immune Therapies, BioPharmaceuticals R&D, AstraZeneca
- Hong Ji
- Translational Medicine, Vaccines & Immune Therapies, BioPharmaceuticals R&D, AstraZeneca
- Anna Kushnir
- Translational Medicine, Vaccines & Immune Therapies, BioPharmaceuticals R&D, AstraZeneca
- Amanda Leach
- Clinical Development, Vaccines & Immune Therapies, BioPharmaceuticals R&D, AstraZeneca
- Shabir A. Madhi
- South African Medical Research Council Vaccines and Infectious Diseases Analytics Research Unit, Faculty of Health Sciences, University of the Witwatersrand
- Vaishali S. Mankad
- Clinical Development, Vaccines & Immune Therapies, BioPharmaceuticals R&D, AstraZeneca
- Eric A. F. Simões
- University of Colorado School of Medicine and Children’s Hospital Colorado
- Benjamin Sparklin
- Bioinformatics, Vaccines & Immune Therapies, BioPharmaceuticals R&D, AstraZeneca
- Scott D. Speer
- Translational Medicine, Vaccines & Immune Therapies, BioPharmaceuticals R&D, AstraZeneca
- Ann Marie Stanley
- Translational Medicine, Vaccines & Immune Therapies, BioPharmaceuticals R&D, AstraZeneca
- David E. Tabor
- Translational Medicine, Vaccines & Immune Therapies, BioPharmaceuticals R&D, AstraZeneca
- Ulrika Wählby Hamrén
- Clinical Pharmacology and Quantitative Pharmacology, R&D, AstraZeneca
- Elizabeth J. Kelly
- Translational Medicine, Vaccines & Immune Therapies, BioPharmaceuticals R&D, AstraZeneca
- Tonya Villafana
- Clinical Development, Vaccines & Immune Therapies, BioPharmaceuticals R&D, AstraZeneca
- DOI
- https://doi.org/10.1038/s41467-024-47421-2
- Journal volume & issue
-
Vol. 15,
no. 1
pp. 1 – 2
Abstract
No abstracts available.